HAVCR2 Overexpression

CI-VAR-00003143Explore in graph →CIViC 486

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma2
HAVCR2 Overexpression	PD1 Inhibitor	Predictive	C	Supports Resistance	3	accepted	EID1150 In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC) PMID 26883990 · Koyama et al., 2016 · Open in CIViC	civic
HAVCR2 Overexpression	Anti-TIM-3 Monoclonal Antibody + PD1 InhibitorCombination	Predictive	D	Supports Sensitivity Response	3	accepted	EID1151 In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC) PMID 26883990 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.